Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims And Supporting Scientific Innovation
Portfolio Pulse from Happy Mohamed
The US Supreme Court has unanimously struck down Amgen's PCSK9 patent claims, ending a nearly decade-long dispute with Regeneron Pharmaceuticals. The decision supports Regeneron's position and affirms the Federal Circuit's opinion that Amgen's patent claims were invalid.
May 18, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amgen's PCSK9 patent claims have been unanimously struck down by the US Supreme Court, ending a nearly decade-long dispute with Regeneron Pharmaceuticals.
The Supreme Court's decision is a significant loss for Amgen, as it invalidates their patent claims and ends the long-standing dispute. This outcome could negatively impact investor confidence in the company and potentially affect its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals wins a unanimous Supreme Court decision, striking down Amgen's PCSK9 patent claims and ending a nearly decade-long dispute.
The Supreme Court's decision is a significant victory for Regeneron, as it validates their position and ends the long-standing patent dispute. This outcome supports Regeneron's innovation and could potentially boost investor confidence in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100